The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 30, 2021
Filed:
Aug. 29, 2019
Applicant:
Bristol-myers Squibb Company, Princeton, NJ (US);
Inventors:
James Aaron Balog, Lambertville, NJ (US);
Steven P. Seitz, Swarthmore, PA (US);
Susheel Jethanand Nara, Mumbai, IN;
Saumya Roy, Bangalore, IN;
Srinivasan Thangathirupathy, Hosur, IN;
Soodamani Thangavel, Krishnagiri, IN;
Ramesh Kumar Sistla, Bangalore, IN;
Assignee:
Bristol-Myers Squibb Company, Princeton, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/5377 (2006.01); C07D 231/12 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 261/08 (2006.01); C07D 277/22 (2006.01); C07D 285/08 (2006.01); C07D 211/60 (2006.01); C07D 317/50 (2006.01); C07D 307/36 (2006.01); C07D 333/54 (2006.01); C07D 231/56 (2006.01); C07D 221/22 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/17 (2006.01); A61K 31/4439 (2006.01); A61K 31/506 (2006.01); A61K 31/42 (2006.01); A61K 31/426 (2006.01); A61K 31/433 (2006.01); A61K 31/357 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); C07C 275/42 (2006.01);
U.S. Cl.
CPC ...
A61K 31/415 (2013.01); A61K 31/17 (2013.01); A61K 31/341 (2013.01); A61K 31/357 (2013.01); A61K 31/381 (2013.01); A61K 31/42 (2013.01); A61K 31/426 (2013.01); A61K 31/433 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); C07C 275/42 (2013.01); C07D 211/60 (2013.01); C07D 221/22 (2013.01); C07D 231/12 (2013.01); C07D 231/56 (2013.01); C07D 261/08 (2013.01); C07D 277/22 (2013.01); C07D 285/08 (2013.01); C07D 307/36 (2013.01); C07D 317/50 (2013.01); C07D 333/54 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.